NEW YORK (GenomeWeb) – Agilent Technologies said on Monday that Genetic Technologies has dismissed its lawsuit against the company alleging patent infringement.
In return, Agilent dismissed its counterclaims against Genetic Technologies of non-infringement and invalidity. No settlement was involved, Agilent said.
Genetic Technologies sued Agilent in 2011 claiming Agilent's Bioanalyzer, genomic hybridization microarrays, and GeneSpring software products infringed US Patent No. 5,612,179 owned by Genetic Technologies. The patents relates to methods of analyzing non-coding DNA sequences. Genetic Technologies, an Australian molecular diagnostics firm, has sued numerous companies in recent years alleging infringement of the '179 patent.
Agilent said that it has maintained that none of its products perform the methods claimed in the patent and that no Agilent customer has ever used the company's product to perform such methods. "Although Agilent respects valid, enforceable intellectual property rights of others, we will vigorously defend what we believe to be unfounded claims of infringement," Agilent Senior Vice President and General Counsel Marie Oh Huber said in a statement.
Earlier this year, the US District Court for the Northern District of California denied Agilent's motion to dismiss Genetic Technologies' lawsuit.